Medicilon is a leading CRO company that provides comprehensive drug R&D services on a global scale. From drug discovery, pharmaceutical research to preclinical research, Medicilon has supported more than 2000 client R&D programs worldwide resulting in 520 IND filings. With proven scientific excellence and FDA-aligned methodologies, we help biotech and pharmaceutical innovators fast-track their path from discovery to IND success. | Medicilon is a leading CRO company that provides comprehensive drug R&D services on a global scale. Medicilon has 21 years experience in the industry and has supported more than 2000 client R&D programs worldwide resulting in 580 IND filings. The company has over 441,320 ft2 of chemistry labs with > 1300 chemists located at three different sites. With operations in the USA, China, and Europe, Medicilon is a leading CRO offering integrated pharmaceutical R&D services, including DMPK/PD, toxicology (GLP and non-GLP), chemistry, discovery biology, and CMC research. In addition, Medicilon offers attractive large animal models (non-human primates, dogs, rabbits, and miniature pigs), tumor & non-tumor animal models (including Xenograft models, PDX / PDXO models), and support for simultaneous U.S. IND filing to streamline global drug development and approval.
LTS Lohmann Therapy Systems
LTS LOHMANN Therapie-Systeme AG is a leading pharmaceutical technology company that develops and manufactures innovative drug delivery systems such as Transdermal Patches (TTS) and Oral Thin Films (OTF) for the pharmaceutical industry. LTS is also advancing emerging drug delivery technologies like Micro Array Patches (MAP) for the transdermal delivery of large molecules, biological actives and vaccines. LTS´s commercial offering encompasses more than 20 marketed products and a diverse pipeline of more than 30 development projects targeting multiple disease indications. LTS’s innovation pipeline contains both partner-funded as well as proprietary, LTS-funded projects. Founded in 1984, LTS operates today from three sites: Andernach, Germany, West Caldwell, NJ, USA and St. Paul, MN, USA. LTS has also a representative office in Shanghai, China. | We CARE. We CREATE. We DELIVER. The driving philosophy behind LTS. As a trusted technology partner for the pharmaceutical industry, we develop and manufacture innovative drug delivery systems such as Transdermal Patches (“TTS”) and Oral Thin Films (“OTF”) as well as wearable drug delivery devices (“OBDS”). LTS´ commercial offering encompasses more than 20 marketed products and a diverse pipeline of more than 40 development projects targeting multiple disease indications. LTS’s innovation pipeline contains both partner-funded as well as proprietary, LTS-funded projects. LTS maintains its leading position through the continuous refinement of its core TTS and OTF technologies and by advancing emerging drug delivery technologies, including Microneedle Array Patches (“MAP”) for the transdermal delivery of small and large molecules, biological actives and vaccines. With its Sorrel(TM) wearable drug delivery platform LTS offers patient friendly solutions for complex drugs delivery at home. Founded in 1984, LTS operates today from four sites: in Andernach, Germany, West Caldwell, NJ, USA, St. Paul, MN, USA and Netanya, Israel. LTS has also a representative office in Shanghai, China. | LTS is a trusted technology partner for the pharmaceutical industry. We develop and manufacture innovative drug delivery systems such as Transdermal Patches (“TTS”) and Oral Thin Films (“OTF”) as well as wearable drug delivery devices (“OBDS”). We are also advancing emerging drug delivery technologies, including Microneedle Array Patches (“MAP”) for the transdermal delivery of small and large molecules, biological actives and vaccines. LTS´ commercial offering encompasses more than 20 marketed products and a diverse pipeline of more than 40 development projects targeting multiple disease indications. LTS’s innovation pipeline contains both partner-funded as well as proprietary, LTS-funded projects. Founded in 1984, LTS operates today from four sites: in Andernach, Germany, West Caldwell, NJ, USA, St. Paul, MN, USA and Netanya, Israel. LTS has also a representative office in Shanghai, China.
LOTTE BIOLOGICS
LOTTE BIOLOGICS is a global CDMO company committed to provide good quality biopharmaceutical products that enable a healthier world. Since established in 2022, with unwavering dedication and distinction, LOTTE BIOLOGICS has successfully transformed into a global CDMO company following the acquisition of Bristol Myers Squibb’s Syracuse manufacturing site. Furthermore, with a plan for Mega Plants in Korea with a total capacity exceeding 360,000L, LOTTE BIOLOGICS aims to become a Global Top 10 CDMO company in the biopharmaceutical industry. In terms of capabilities, LOTTE BIOLOGICS can offer a comprehensive range of services, from cell line development to clinical and commercial supply of Biologics Drug Substance manufacturing. The production capacity at the Syracuse site is 35,000L (5,000L x7), along with multiple 1,100 L bioreactors for clinical product production, QC testing laboratories, a warehouse, cell bank and product storage and other related facilities. In addition, the Syracuse site has a proven regulatory track record with more than 62 global approvals including from FDA, EMA, PMDA and MFDS. In addition, ADC conjugation facility is currently being installed to meet the increasing demand in the market. The Mega Plants in South Korea, with a total capacity exceeding 360,000L, are scheduled to be GMP ready starting from the year of 2026. In order to foster growth and innovation in the biopharmaceutical industry, “LOTTE Bio Initiatives” will be established on the Mega Plant Campus to provide a platform for bioecosystem. Together with our partners, LOTTE BIOLOGICS is dedicated to providing reliable solution for development, manufacturing and supply of the biopharmaceutical products. For more information, please visit https://www.lottebiologics.com/en | LOTTE BIOLOGICS is a global CDMO company committed to provide good quality biopharmaceutical products that enable a healthier world. Since established in 2022, with unwavering dedication and distinction, LOTTE BIOLOGICS has successfully transformed into a global CDMO company following the acquisition of Bristol Myers Squibb’s Syracuse manufacturing site. Furthermore, with a plan for Songdo Bio Campus in Korea with a total capacity up to 360,000L, LOTTE BIOLOGICS aims to become a Global Top 10 CDMO company in the biopharmaceutical industry. In terms of capabilities, LOTTE BIOLOGICS can offer a comprehensive range of services, from cell line development to clinical and commercial supply of Biologics Drug Substance manufacturing. The production capacity at the Syracuse Bio Campus is 40,000L (5,000L x8), along with multiple 1,100 L bioreactors for clinical product production, QC testing laboratories, a warehouse, cell bank and product storage and other related facilities. In addition, the Syracuse Bio Campus has a proven regulatory track record with more than 62 global approvals including from FDA, EMA, PMDA and MFDS. In addition, ADC conjugation facility is currently being installed to meet the increasing demand in the market, which is projected to be fully in operation by Q1 2025. The Songdo Bio Campus in South Korea, with a total capacity up to 360,000L, are scheduled to be GMP ready starting from the year of 2026. In order to foster growth and innovation in the biopharmaceutical industry, “LOTTE Bio Initiatives” will be established on the Songdo Bio Plant Campus to provide a platform for bioecosystem. Together with our partners, LOTTE BIOLOGICS is dedicated to providing reliable solution for development, manufacturing and supply of the biopharmaceutical products. For more information, please visit https://www.lottebiologics.com/en | LOTTE BIOLOGICS was established in 2022 and is headquartered in Seoul, South Korea. Utilizing a two-track strategy of acquiring and building, LOTTE BIOLOGICS is solidifying its competitiveness in the CDMO market. At the Syracuse Bio Campus in New York, LOTTE BIOLOGICS provides high-quality GMP manufacturing services for drug substances. The facility offers a total production capacity of 40,000L, supported by eight 5,000L stainless steel bioreactors. Additionally, the campus includes extensive analytical QC testing laboratories and warehouse facilities that have received over 62 regulatory approvals from agencies worldwide. LOTTE BIOLOGICS is also advancing into a new area of expertise with Antibody-Drug Conjugates (ADCs) services. With over $100 million invested in ADC modalities, including both drug substance and conjugation capabilities on-site, we offer a seamless, end-to-end service from drug substance manufacturing to conjugation. Looking ahead, LOTTE BIOLOGICS is constructing three advanced bio plants in Songdo, South Korea. With construction of the first plant already underway and expected to be operational by 2027, each facility will feature eight 15,000L stainless steel bioreactors for large-scale commercial production, along with multiple 3,000L bioreactors to meet clinical production needs. Collectively, these plants will provide a manufacturing volume exceeding 360,000L in bioreactor capacity. Through our commitment to delivering innovative medicines to patients worldwide, LOTTE BIOLOGICS aims to become a top-tier global CDMO company in the biopharmaceutical industry.
Kemwell Biopharma Private Ltd.
Kemwell is a biologics focused Contract Development and Manufacturing (CDMO) company providing services to global biopharmaceutical organisations. Kemwell’s facilities, located in Bangalore, India, are designed with technological support from a leading German biopharma company.The team is experienced to undertake end-to-end activities right from cell line development till cGMP clinical and commercial manufacturing. Kemwell also undertakes standalone projects such as process optimisation, analytical method development or validation, formulation development and optimization, stability studies, resin reuse study, tech transfer and cGMP manufacturing, process characterization, etc. We are currently supplying commercial mAb in 35 plus countries and have worked with US innovator/biotech companies to accelerate development for their pipeline drugs since 2012. | As a trusted biologics CDMO partner we provide end-to-end service from clinical development to commercial-scale manufacturing, we have an extensive process characterization infrastructure and experience in process development including complex mAbs – (Bispecific, Trispecific, ADC and Complex fusion proteins), Analytical Development (Bioassays, Mass Spec, and SPR), and formulation development (in-house stability studies, Liquid, Lyo, and high concentration protein formulation). To enhance our drug product fill-finish capabilities, we have introduced the OPTIMA Pre-Filled Syringe line, in addition to our existing liquid and lyophilized vial offerings. | Kemwell has 40+ years of experience being a CDMO based out of Bangalore, India and provides services to global biopharmaceutical organisations. Our FDA-approved site supports end-to-end biologics programs from development to commercial supply and features: • 5000L+ upstream capacity with single-use and stainless-steel bioreactors • Commercial fill-finish lines for liquid vials, lyo vials and pre-filled syringes with isolator technology • Capabilities across monoclonals, bispecifics/tri-specifics, fusion proteins, biosimilars
KBI BioPharma, Inc.
KBI Biopharma, Inc. KBI Biopharma, a JSR Life Sciences company, is a leading global contract development and manufacturing organization (CDMO) providing fully integrated, accelerated drug development and biologics manufacturing services and expertise to life science companies. With each of its 500+ client partners, KBI works closely to personalize and accelerate drug development programs. Built upon a foundation of world-class analytics capabilities and extensive scientific and technical expertise, KBI delivers robust process development and clinical and commercial cGMP manufacturing services for mammalian, microbial, and cell therapy programs. Recognized for quality manufacturing, KBI helps clients advance drug candidates into the clinic and beyond. KBI serves its global clients with multiple locations in Europe and the USA. www.kbibiopharma.com. Selexis SA Selexis SA, a JSR Life Sciences company, is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. Our global partners are utilizing Selexis technologies to advance more than 160 drug candidates in preclinical and clinical development and the manufacture of ten commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks. More information is available at www.selexis.com | KBI Biopharma, Inc., a JSR Life Sciences company, together with its affiliates, is a global contract development and manufacturing organization (CDMO) providing fully integrated, accelerated drug development and biologics manufacturing services and expertise to life science companies. As a global leader in mammalian cell line development, with best-in-class modular technology and highly specialized solutions, KBI enables the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. With each of its 500+ client partners, KBI works closely to personalize and rapidly accelerate drug development programs. Global partners are utilizing KBI’s technologies to advance more than 170 drug candidates in preclinical and clinical development and the manufacture of ten commercial products. Built upon a foundation of world-class analytics capabilities and extensive scientific and technical expertise, KBI delivers robust process development and clinical and commercial cGMP manufacturing services for mammalian, microbial, and cell therapy programs. Recognized for quality manufacturing, KBI helps partners advance drug candidates to the market. KBI serves its global partners with eight locations in Europe and the USA. More information is available at www.kbibiopharma.com. | KBI Biopharma, a JSR Life Sciences company, is your expert CDMO partner for complex biologics. From development through manufacturing, trust us to solve your challenges, so you can focus on what matters most – the cures. With expertise that accelerates your path to clinic and market through advanced platforms for mammalian and microbial production, deep CMC and analytical capabilities, and end-to-end CLD-to-vial services, KBI biopharma helps you bring even your most challenging molecules to clinic and market with confidence. With platforms that accelerate your path to clinic and market, KBI Biopharma brings deep expertise across mammalian and microbial production, CMC strategy, and advanced analytics. Our end-to-end services, from cell line development to drug product, are built to help you confidently advance even the most complex molecules. Whether it’s mammalian cell line development powered by Selexis®, high-yield PUREcoli™ microbial strains, or robust manufacturing solutions, our integrated approach simplifies your journey from concept to commercialization. You’ll also benefit from PROGRAMview™, our innovative digital platform that brings a new standard of transparency to CDMO partnerships, giving your team real-time access to data, smarter decision-making, and milestone-driven execution. With dual operations in the U.S. and Europe and over 170 molecules supported, we deliver global regulatory insight and solutions tailored to your unique program needs. | KBI Biopharma is the CDMO of choice for complex biologics and expert analytics, helping life science companies accelerate the development and manufacture of innovative therapies and vaccines. With roots in analytical services and deep technical expertise in mammalian and microbial programs, KBI provides process development, analytical, and cGMP manufacturing services across the drug development lifecycle. KBI’s technologies support more than 250 drug candidates in preclinical and clinical development and 15 marketed products. KBI partners with customers to solve challenges, drive breakthroughs, and advance programs to market – serving customers from six locations across the US and Europe. Learn more at www.kbibiopharma.com.
JIANGSU YAOHAI BIO-PHARMACEUTICAL Co. ,Ltd
Yaohai Biopharmaceutical Co., Ltd. was founded in August 2010. It has served as a Microbial CRDMO (Contract Research, Development, and Manufacturing Organization) specializing in microbial expression systems and offering one-stop services, including microbial strain engineering, microbial cell banking, process development, pilot scale-up, cGMP-guided manufacturing, fill and finish, analysis and testing, etc. Since its establishment, we have been focusing on “VLP vaccine, peptide, cytokine, nano-antibody, enzyme, plasmid DNA, mRNA, and others recombinant proteins or nucleic acids” as vaccines or therapeutics for human, veterinary, and pet health management. | Yaohai Bio-Pharma, founded in August 2010, is a specialized Microbial CRDMO (Contract Research, Development, and Manufacturing Organization) offering end-to-end services based on microbial expression systems. Our integrated solutions span strain engineering, cell banking, process development, cGMP manufacturing, analytical testing, fill-finish, and regulatory support. We focus on recombinant protein/peptide, nano-body, mRNA, plasmid DNA, VLP vaccines and other modalities for both human and veterinary use. Core Strengths: 1. Comprehensive Service Platform: Covering the full development cycle—from preclinical to commercial production—under global regulatory standards (NMPA, FDA, EMA). 2. Advanced Manufacturing Capacity: 5 drug substance lines with a total microbial fermentation capacity of 7,500L (2L–2,000L), plus 2 drug product workshops for sterile fill-finish of vials (liquid/lyophilized powder) and pre-filled syringes/cartridges. 3. Scalable Solutions: Supporting rapid scale-up with GMP-compliant facilities and fermentors ranging from 2L to 2,000L. 4. Proven Expertise: A seasoned team with 15+ years of experience, delivering over 200 successful projects across diverse therapeutic areas.
Iris Biotech GmbH
Iris Biotech is providing high quality products for the fields peptide synthesis, linkerology, drug delivery, and life sciences in flexible quantities from research scale to commercial production, for academia as well as industry. Besides our broad portfolio from standard to exotic, we have the know-how and facilities to manufacture your compound of choice based on a Custom Synthesis. All our services are rounded off by a strong and competent personnel customer support. We are in continuous exchange with scientists all around the world to gather ideas and be ahead regarding technologies and innovations true to our slogan Empowering Peptide Innovation. | Founded in 2001, Iris Biotech provides scientists in both industry and academia with innovative and rare compounds, while also being your reliable partner for a comprehensive supply of standard consumables. Guided by our dedication to deliver competent service as well as the highest quality to our customers, our company’s focus remains Peptide Chemistry, while we also have strong expertise in Drug Delivery, Life Sciences, and Linkerology. Due to the growing demand for tailor-made compounds and solutions, we further increased our Custom Synthesis capabilities in 2013. Our skilled scientists and technicians offer profound expertise in the custom manufacturing of both simple and complex molecules. | Empowering Peptide Innovation With this guiding theme in mind, Iris Biotech’s mission is to support researchers by supplying • innovative technologies, • rare compounds, • as well as a broad portfolio on standard consumables, available in flexible quantities from small scale to bulk quantities. Guided by our dedication to provide • competent service, • as well as novel substances and • latest technologies, Iris Biotech is your trusted partner for the world of peptides, while having strong expertise in associated disciplines. Thus, our portfolio comprises reagents and tools for the synthesis and modification of peptides, e.g., amino acids, resins and solvents but also for related technologies such as drug delivery, linkerology® and life sciences. Your project requires a compound not listed in our portfolio? Get in contact and inquire about our custom synthesis capabilities. | Empowering Peptide Innovation – this is our guiding principle. Iris Biotech stands for innovation and know-how in the field of pharmaceuticals and biotechnology. With this guiding theme in mind, Iris Biotech attends various conferences, symposia and exhibitions each year, which allows us to remain in direct contact with scientists from academia and industry alike, in order to exchange knowledge, and to gather new ideas to tackle your current challenges. Our mission as qualified supplier and competent consultant is to support our customers in their ongoing projects from research scale to commercial production.
IPCA LABORATORIES PVT. LTD.
Ipca Laboratories Ltd. is a global, consumer-led pharmaceutical company committed to improving lives since 1949. For over 60 years, Ipca has been a trusted healthcare partner across more than 120 countries spanning six continents. We are a fully integrated pharmaceutical company with capabilities in the manufacture of over 350 formulations and 80 APIs across multiple therapeutic segments, supported by 35 manufacturing facilities and 8 R&D centers. Our state-of-the-art R&D center in Mumbai, along with our advanced manufacturing facility in Pithampur, Madhya Pradesh, specializes in the development and biomanufacturing of monoclonal antibody (mAb) biosimilars. The facility adheres to global GMP standards and produces high-potency biosimilars for both domestic and regulated international markets, including the USA and Europe. It is equipped with single-use Drug Substance (DS) and Drug Product (DP) systems, automated processes, a zero liquid discharge effluent treatment plant, and environmentally sustainable practices. Ipca is also among the fastest-growing companies within the top 20 pharmaceutical companies in India. We believe there is strong potential for collaboration between our organizations in the biosimilars space. Possible areas of partnership include: Drug Substance and Drug Product development and manufacturing In-licensing and out-licensing of monoclonal antibody (mAb) molecules Technology transfer and know-how sharing Peer-to-peer biosimilar business development across global markets We have developed a robust biosimilar pipeline (mAb and non-mAb) targeting key markets including the EU, UK, USA, Canada, Japan, India, and Rest of the World (ROW).
INTRAVACC
Intravacc is an established independent CDMO with years of experience in developing and optimizing vaccines for infectious diseases and therapeutic vaccines, which has transferred its technology worldwide for vaccines against polio, measles, diphtheria, Hib, and influenza. Around 30% of childhood disease vaccines are based on Intravacc’s technology and knowhow. Intravacc offers a wide range of expertise for independent vaccine development, from concept to Phase I/II clinical studies, for customers around the world. Intravacc continues to capitalize on the critical global trends in healthcare: the ever-growing need for prevention and intervention for infectious diseases and cancer. Our innovative vaccine platforms and vaccine contract development and manufacturing capabilities are well positioned to address the unmet needs in the vaccine and immune therapy market which is currently estimated at $37 billion in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 6.6% to $55 billion by 2027. The company’s head office is located on the Utrecht Science Park location Bilthoven, The Netherlands, and has state-of-the-art laboratories and GMP production facilities. Intravacc B.V. is a limited liability company incorporated under Dutch law. Intravacc is a state holding company since 1 January 2021, under the Ministry of Health, Welfare and Sports (VWS). | . | Your specialized CDMO to accelerate the development of your viral, bacterial, therapeutic, and conjugate vaccines. From discovery to phase II clinical trial. Based in the Netherlands within the Utrecht Science Park in Bilthoven, Intravacc is a globally recognized pioneer and leader in translational vaccinology. With decades of experience, we stand as an independent Contract Development and Manufacturing Organization (CDMO) within the vaccine industry. Our purpose is to serve as the vital link between your discoveries and early-stage clinical trials of new vaccines. We understand that this journey from concept to GMP production is often riddled with challenges, and we specialize in mitigating risks and reducing costs. | Your specialized CDMO for viral, bacterial, therapeutic, and conjugate vaccines Based in the Netherlands and nestled within the Utrecht Science Park in Bilthoven, Intravacc is a globally recognized leader in translational vaccinology. With decades of experience, we stand as an independent Contract Development and Manufacturing Organization (CDMO) within the vaccine industry. Our purpose is to serve as the vital link between your discoveries and early-stage clinical trials. We understand that this journey from concept to GMP production is often riddled with challenges, and we specialize in mitigating risks and reducing costs. The entire team at Intravacc is committed to blazing new paths in vaccine development. We have an exceptional track record imagining and realizing technologies that enable tomorrow’s vaccines. That expertise in vaccine development is at the core of our CDMO services and candidate vaccines out-licensing.